Explore the words cloud of the CHARME project. It provides you a very rough idea of what is the project "CHARME" about.
The following table provides information about the project.
KUROS BIOSCIENCES BV
|Coordinator Country||Netherlands [NL]|
|Total cost||2˙630˙845 €|
|EC max contribution||1˙841˙591 € (70%)|
1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
|Duration (year-month-day)||from 2015-07-01 to 2017-06-30|
Take a look of project's partnership.
|1||KUROS BIOSCIENCES BV||NL (BILTHOVEN)||coordinator||1˙841˙591.00|
XPAND Biotechnology BV has developed a new generation of orthopaedic materials: the EpitaxOs bone regeneration material.
EpitaxOs (TRL 6) is unique: a) it seduces the body to form bone b) is as effective as the golden standard autograft without its disadvantages (extra operative procedure, pain, limited quantity available) c) it is superior to other synthetic bone graft materials, allograft, growth factors and cell-based technologies d) it is available in abundant quantities e) it increases the quality of life for patients as the use of EpitaxOs has no adverse effects on the patient. The innovative property of EpitaxOs is its patented surface nano-structure, which induces the formation of bone by attracting the patient’s own stem cells to the defect site and stimulate them to make autologous bone (in situ bone tissue regeneration). Similar to autograft and growth factors and unlike other synthetic materials, EpitaxOs is a true bone inducing material, but generates bone much faster
EpitaxOs is targeted at the €4 billion spinal market and the €200 million dental market. The exceptional bone inducing properties of EpitaxOs put it in a unique position to replace autograft, (processed) allograft and growth factors.
The CHARME project aims at bringing EpitaxOs from technological maturity level TRL6 to a successful commercial/ production launch at level TRL 8/9 (in 2017). The objectives are: 1. Development of a commercial scale production infrastructure 2. Regulatory submission of EpitaxOs in key markets 3. Providing evidence-based data to demonstrate product superiority and facilitate product launch & market acceptance 4. Establishment of a marketing channel and development of a strategy for commercialisation of EpitaxOs
The endpoints of the CHARME project will be EpitaxO, a commercial scale infrastructure, to manufacture EpitaxOs, regulatory submission, approval in Europe, clinically relevant study data, a marketing channel, plan for the commercialisation
|Distribution targeted information letters to dedicated groups||Other||2019-07-25 13:42:30|
|Scientific articles||Documents, reports||2019-07-25 13:42:30|
|Brochures for patients, surgeons, hospitals||Other||2019-07-25 13:42:30|
|Establish an interactive CHARME webpage.||Other||2019-07-25 13:42:30|
Take a look to the deliverables list in detail: detailed list of CHARME deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHARME" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CHARME" are provided by the European Opendata Portal: CORDIS opendata.
Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.Read More
In-Line Areal Surface Measurement for Micro and Nano ProductionRead More
High volume production facility for high accuracy nanocapsulesRead More